clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
glukosamin pharma nord 400 mg kapsel, hård
pharma nord aps - glukosaminsulfatkaliumklorid - kapsel, hård - 400 mg - glukosaminsulfatkaliumklorid 675,9 mg aktiv substans - glukosamin
skytrofa (previously lonapegsomatropin ascendis pharma)
ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiska och hypotalamiska hormoner och analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.
clindamycin eql pharma 150 mg kapsel, hård
eql pharma ab - klindamycinhydroklorid - kapsel, hård - 150 mg - klindamycinhydroklorid 162,88 mg aktiv substans; laktosmonohydrat hjälpämne
clindamycin eql pharma 300 mg kapsel, hård
eql pharma ab - klindamycinhydroklorid - kapsel, hård - 300 mg - laktosmonohydrat hjälpämne; klindamycinhydroklorid 325,8 mg aktiv substans
tadalafil teva pharma 20 mg filmdragerad tablett
teva pharma bv - tadalafil - filmdragerad tablett - 20 mg - tadalafil 20 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne
tadalafil teva pharma b.v. 20 mg filmdragerad tablett
teva pharma bv - tadalafil - filmdragerad tablett - 20 mg - laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne; tadalafil 20 mg aktiv substans
cabergoline teva pharma 1 mg tablett
teva pharma bv - kabergolin - tablett - 1 mg - laktos (vattenfri) hjälpämne; kabergolin 1 mg aktiv substans - kabergolin
cabergoline teva pharma 2 mg tablett
teva pharma bv - kabergolin - tablett - 2 mg - kabergolin 2 mg aktiv substans; laktos (vattenfri) hjälpämne - kabergolin
zoledronic acid oresund pharma 4 mg/100 ml infusionsvätska, lösning
Øresund pharma aps - zoledronsyramonohydrat - infusionsvätska, lösning - 4 mg/100 ml - mannitol hjälpämne; zoledronsyramonohydrat 4,264 mg aktiv substans